Although Bcl-2 was shown to be related to decreased survival and malignant potential in urothelial transitional cell cancer (Bilim et al, 1996), oesophagus cancer (Hsia et al, 2001), prostate cancer (Bauer et al, 1996) and other cancers, we demonstrated here that Bcl-2 is an independent favourable prognostic factor in RCC patients. The gene discussed is BCL2; the disease is Familial prostate cancer.